Skip to main content
    S

    Silence Therapeutics PLC (SLN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.87
    -0.78 (-8.08%)

    Market Cap: $558.14M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(14/22)
    Avg Surprise
    +139.82%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.10+10.0%
    60d ago$-0.10+10.0%
    30d ago$-0.18+50.0%
    7d ago$-0.18+50.0%
    Current$-0.09
    Revenue Consensus
    $20670
    Range$0 - $124000
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.06
    Range$-0.06 - $-0.05
    2 analysts
    Revenue Consensus
    $-2840280
    Range$-2866720 - $-2700720
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.06---
    Sep 26EST
    		-$-0.09---
    Jun 26
    Reported Aug 10
    		$-0.26$-0.32+18.75%Beat+51.9%
    Mar 26
    Reported May 7
    		$-0.33$-0.23-44.36%Miss+45.0%
    Dec 25
    Reported Mar 5
    		$-0.27$-0.49+44.90%Beat-258.8%
    Sep 25
    Reported Nov 6
    		$-0.15$-0.21+28.57%Beat+79.5%
    Jun 25
    Reported Aug 7
    		$-0.54$-0.27-100.00%Miss-25.6%
    Mar 25
    Reported May 8
    		$-0.60$-0.41-46.34%Miss-1009.1%
    Dec 24
    Reported Feb 27
    		$0.17$-0.25+169.33%Beat+135.4%
    Sep 24
    Reported Nov 14
    		$-0.73$-0.13-461.54%Miss-170.4%
    Jun 24
    Reported Aug 15
    		$-0.43$-0.11-290.91%Miss-16.2%
    Mar 24
    Reported May 16
    		$-0.05N/A+52.71%Beat+54.3%
    Dec 23
    Reported Mar 13
    		$-0.48$-0.21-128.57%Miss-206.1%
    Sep 23
    Reported Nov 14
    		$-0.27$-0.38+28.95%Beat-221.0%
    Jun 23
    Reported Aug 16
    		$-0.37$-0.67+44.78%Beat-143.7%
    Mar 23
    Reported May 16
    		$-0.12$-0.15+21.28%Beat-12.3%
    Dec 22
    Reported Mar 15
    		$0.45$-0.01+3748.39%Beat+417.9%
    Sep 22
    Reported Nov 10
    		$-0.08N/A+58.18%Beat+43.6%
    Jun 22
    Reported Aug 11
    		$-0.15$-0.20+22.59%Beat+51.8%
    Mar 22
    Reported May 16
    		$-0.11$-0.19+44.76%Beat+81.0%
    Dec 21
    Reported Mar 17
    		$-0.14$-0.14-0.42%Miss+9.2%
    Sep 21
    Reported Nov 16
    		$-0.15$-0.15+1.97%Beat+16.0%
    Jun 21
    Reported Aug 12
    		$-0.31N/A-136.91%Miss-121.8%
    Mar 21
    Reported Jun 2
    		$-0.55$-0.55+0.00%Beat-553.5%
    Dec 20
    Reported Mar 30
    		$-0.16$0.00N/AMiss-84.5%
    Sep 20
    Reported Dec 31
    		$-0.18$0.00N/AMiss-86.1%
    Jun 20
    Reported Sep 30
    		$-0.14$0.00N/AMiss-60.3%
    Mar 20
    Reported Jun 30
    		$-0.08$0.00N/AMiss-15.8%
    Dec 19
    Reported Mar 31
    		$-0.09$0.00N/AMiss-13.2%
    Sep 19
    Reported Dec 31
    		$-0.10$0.00N/AMiss-8.5%
    Jun 19
    Reported Sep 30
    		$-0.09$0.00N/AMiss+1.4%
    Mar 19
    Reported Jun 30
    		$-0.07$0.00N/AMiss+10.6%
    Dec 18
    Reported Mar 31
    		$-0.08$0.00N/AMiss+13.7%
    Sep 18
    Reported Dec 31
    		$-0.09$0.00N/AMiss-333.5%
    Jun 18
    Reported Sep 30
    		$-0.09$0.00N/AMiss-340.8%
    Mar 18
    Reported Jun 30
    		$-0.08$0.00N/AMiss-59.3%
    Dec 17
    Reported Mar 31
    		$-0.09$0.00N/AMiss-75.8%
    Sep 17
    Reported Dec 31
    		$0.04$0.00N/ABeat-
    Jun 17
    Reported Sep 30
    		$0.04$0.00N/ABeat-
    Mar 17
    Reported Jun 30
    		$-0.05$0.00N/AMiss-
    Dec 16
    Reported Mar 31
    		$-0.05$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-8.78EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-10476.00%
    ROE-90.40%ROIC-157.54%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio7.42xQuick Ratio7.42x
    Trading Statistics
    Beta1.45Avg Volume1.01M
    52-Week High$17.5852-Week Low$4.19

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.00
    SMA 20$10.89
    SMA 50$12.45
    SMA 200$8.32
    EMA 10$9.97
    EMA 20$10.73
    EMA 50$11.39
    EMA 200$9.16

    MACD

    Line: -0.90Signal: -0.74Hist: -0.15

    ADX

    ADX: 37.0+DI: 12.4-DI: 34.7

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$10.39

    Bollinger Bands

    Upper Band$13.12
    Lower Band$8.66
    %B Position4090%(Upper)
    Band Width0.05

    RSI (14-Day)

    Oversold
    22.3

    Momentum Oscillators

    Stoch %K15.6
    Stoch %D16.2
    Williams %R-94.6
    ROC (10d)-17.9%
    Momentum-1.93
    CCI (20d)-141.1
    MFI (14d)15.0

    Volatility Measures

    ATR (14d)$0.69(7.8%)
    StdDev (20d)1.11
    Hist Vol45.1%(High)

    Volume Flow

    VWAP$9.05
    OBV6.1M
    AD Line-12.8M
    CMF (20d)-0.295

    Volume Metrics

    Avg Vol (20d)986.2K
    Vol Ratio1.5x
    VWMA (20d)$10.72

    Pivot Points

    R3$10.92
    R2$10.64
    R1$10.14
    Pivot Point$9.86
    S1$9.37
    S2$9.09
    S3$8.59

    Advanced Oscillators

    TSI-44.35
    Ultimate Osc32.3
    KST-237.35

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$421,292$34,000$159,000$307,198$183,706$24.33M$1.14M$598,000$15.70M$2.10M$2.80M
    Cost of Revenue$108,195$116,803$12,000$64,000$116,570$69,860$1.61M$2.77M$2.64M$2.80M$1.35M$1.61M
    Gross Profit$-108,195$304,488$22,000$95,000$190,627$113,846$22.72M$-1,632,000$-2,040,000$12.90M$753,000$1.19M
    Operating Expenses$13.00M$15.33M$12.48M$26.34M$33.05M$36.87M$25.80M$20.91M$16.28M$18.48M$14.05M$13.89M
    R&D$8.31M$8.34M$8.75M$20.54M$24.20M$26.93M$20.40M$15.30M$10.99M$11.85M$9.94M$8.93M
    SG&A$4.69M$7.03M$3.73M$5.79M$7.04M$9.94M$5.40M$5.60M$5.29M$6.63M$4.12M$4.96M
    Operating Income$-13,110,705$-15,020,782$-12,461,000$-26,244,000$-32,863,337$-36,753,007$-3,078,390$-22,537,000$-18,323,000$-5,581,000$-13,299,000$-12,699,000
    Interest Income$0$0$0$0$0$0$0$981,000$1.06M$804,000$388,000$2.05M
    Interest Expense$0$0$0$0$4.64M$11.54M$11.54M$8.60M$183,000$13,000$928,000$8,000
    Income Before Tax$-12,289,219$-14,931,931$-11,770,000$-20,957,000$-37,500,108$-36,909,546$23.74M$-30,158,000$-17,441,000$-2,068,000$-14,966,000$-10,661,000
    Income Tax Expense$1,001$0$-1,000$1,000$13,714$9.56M$9.56M$-3,146,000$-1,879,000$244,000$-554,000$-2,411,000
    Net Income$-12,290,221$-14,931,931$-11,770,000$-20,958,000$-37,513,822$-36,909,546$14.17M$-27,012,000$-15,562,000$-2,312,000$-14,412,000$-8,250,000
    EBITDA$-13,002,705$-14,825,931$-11,657,000$-20,801,000$-30,844,607$-36,731,015$7.19M$-21,441,000$-17,139,000$-2,934,000$-14,908,000$-10,528,000
    EBIT$-13,110,705$-14,931,931$-11,770,000$-20,957,000$-31,047,577$-36,909,546$7.07M$-21,556,000$-17,258,000$-3,086,000$-15,029,000$-10,653,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SLN

    News

    Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    Silence Therapeutics (SLN) has experienced a significant 28.8% stock price drop over the past four weeks. However, technical analysis using the Relative Strength Index (RSI) suggests the stock is now oversold...

    Yahoo Finance Singapore•10/14/26•Bullish

    Call options cover 1.5M shares in an amended stake report for Silence Therapeutics (SLN).

    Tetragon Financial Group Limited and its associated entities have filed an amended Schedule 13G for Silence Therapeutics (SLN), reporting a shared beneficial ownership of 9,878,565 ordinary shares...

    Stock Titan•10/14/26•Neutral

    Call options on 1.5M shares feature in a passive Silence Therapeutics (SLN) stake.

    Tetragon Financial Group Limited and its affiliates have reported a 5.2% passive stake in Silence Therapeutics plc (SLN)...

    Stock Titan•10/13/26•Neutral

    Silence Therapeutics (SLN) Upgraded to Buy: Here's Why

    Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), driven by an upward trend in earnings estimates. This upgrade suggests a positive earnings outlook for the company...

    Yahoo! Finance Canada•10/13/26•Bullish

    Certain Options of Silence Therapeutics plc are subject to a Lock-Up Agreement Ending on 11-OCT-2026.

    Certain Options of Silence Therapeutics plc are subject to a lock-up agreement that will end on October 11, 2026. This lock-up period began on August 11, 2026...

    www.marketscreener.com•10/10/26•Neutral

    SLN Valuation and Fair Value

    P/E
    -8.8x
    P/B
    3.6x
    See GNG's fair value

    SLN Profitability: Margins, ROIC and FCF

    Operating margin
    -10476.0%
    Net margin
    0.0%
    ROIC
    -157.5%
    ROE
    -90.4%
    FCF margin
    -4595.2%

    SLN Competitors

    CompanyTicker
    Sagimet Biosciences Inc. Series A Common StockSGMT
    Valneva SE ADRVALN
    DBV TechnologiesDBVT
    ZimVie IncZIMV
    Prime Medicine, Inc. Common StockPRME
    Bright Minds Biosciences IncDRUG
    Orthopediatrics CorpKIDS
    Shattuck Labs IncSTTK

    Sector: Healthcare

    SLN Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    1
    Buy
    5
    Hold
    0
    Sell
    1
    Strong Sell
    0

    SLN Bull Case vs Bear Case

    Bull case

    • SLN grew quarterly revenue 197.2% year over year.
    • 85.7% of SLN's analyst ratings are Buy or Strong Buy.

    SLN Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -48.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.09
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About SLN

    Does SLN pay dividends?

    Silence Therapeutics PLC (SLN) does not currently pay a regular dividend.

    What is SLN's market cap?

    Silence Therapeutics PLC (SLN) has a market capitalization of $558.14M with a current stock price of $8.87.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In